News Articles Tagged: RTK Inhibitors

Sunitinib Malate Intermediate: The Crucial Role of Ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

This article by NINGBO INNO PHARMCHEM CO.,LTD. focuses on Ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate as a critical intermediate for Sunitinib Malate, a key drug in targeted cancer therapy.

The Role of Ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate in Modern Pharmaceutical Synthesis

NINGBO INNO PHARMCHEM CO.,LTD. explores the critical function of Ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate as a pharmaceutical intermediate, particularly in the synthesis of Sunitinib Malate and other vital medications.

Sorafenib Tosylate: Targeting Cellular Pathways for Effective Cancer Treatment

Examine how Sorafenib Tosylate targets specific cellular pathways, including Raf/MEK/ERK and RTKs, to achieve its potent anti-cancer effects.